Wall Street Analysts Are Bullish on Top Healthcare Picks
at www.tipranks.com (Tue, 3-Nov 12:30 PM)
Syndax’s Strong Commercial Momentum Supports Buy Rating and Unchanged $57 Price Target
at www.tipranks.com (Tue, 3-Nov 5:35 AM)
Syndax Pharmaceuticals (SNDX) Receives a Buy from Barclays
at www.tipranks.com (Tue, 3-Nov 4:27 AM)
Neutral Rating Maintained as Revuforj Adoption Improves; Price Target Unchanged at $33
at www.tipranks.com (Mon, 2-Nov 8:55 PM)
Syndax names Aaron Ondrey CFO as Keith Goldan retires
at seekingalpha.com (Mon, 2-Nov 4:13 PM)
Syndax Pharmaceuticals GAAP EPS of -$0.55 misses by $0.04, revenue of $83.3M beats by $1.49M
at seekingalpha.com (Mon, 2-Nov 4:05 PM)
Here are the major earnings after the close Monday
at seekingalpha.com (Mon, 2-Nov 9:00 AM)
Syndax Pharmaceuticals Q3 2026 Earnings Preview
at seekingalpha.com (Sun, 1-Nov 4:35 PM)
Bank of America Securities Remains a Buy on Syndax Pharmaceuticals (SNDX)
at www.tipranks.com (Fri, 30-Oct 2:16 PM)
Syndax drops after axatilimab misses MAXPIRe IPF endpoint, while cGVHD program stays on track
Market Chameleon (Tue, 13-Oct 10:59 AM)
Syndax halts axatilimab IPF plans after MAXPIRe misses FVC decline endpoint
Market Chameleon (Tue, 13-Oct 7:33 AM)
